Consensus Guidelines and Recommendations for the anti-CD38-based Therapy in Clinical Practice for Relapsed/Refractory Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group.

15.2 months; hazard ratio [HR], 0.64) and showed a favorable trend in OS (50.8 vs. 43.6 months; HR, 0.78; P = 0.042) compared with carfilzomib and dexamethasone (Kd), particularly in high-risk cytogenetics (34.3 vs. 17.1 months; HR, 0.52) and lenalidomide- and PI-refractory patients.

also in 466 other papers

Although the OS benefit did not reach statistical significance, there was a favorable trend, with 48-month OS rates of 59.7% vs. 52.2% in the control arm. 33 The APOLLO trial demonstrated that subcutaneous (SC) daratumumab plus pomalidomide and dexamethasone (Pd) significantly improved PFS compared to Pd alone (24.4 vs. 17.6 months; HR, 0.73), with a favorable

also in 33,519 other papers